1. Potential role for all-trans retinoic acid in nonpromyelocytic acute myeloid leukemia
   Hayley S Ma et al, 2016, International Journal of Hematologic Oncology CrossRef
2. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
   Noortje van Gils et al, 2017, Experimental Hematology CrossRef
3. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways
   Li-Na Wang et al, 2017, Leukemia & Lymphoma CrossRef
4. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo
   Hayley S. Ma et al, 2016, Blood CrossRef
5. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
   Molly M. Gallogly et al, 2017, Therapeutic Advances in Hematology CrossRef
6. Molecular Interaction Between the Microenvironment and FLT3/ITD+ AML Cells Leading to the Refractory Phenotype
   Seiji Fukuda et al, 2018, Myeloid Leukemia CrossRef
7. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
   Hao Lu et al, 2022, BMC Cancer CrossRef